PharmGen Science Inc Total Liabilities
PharmGen Science Inc total liabilities. Based on the latest financial reports, PharmGen Science Inc (004720) has total liabilities worth ₩83.70 Billion KRW (≈ $56.72 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 004720 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of PharmGen Science Inc (2004–2024)
Total liabilities of PharmGen Science Inc from 2004 to 2024. This chart illustrates how PharmGen Science Inc's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of PharmGen Science Inc to see how much of total assets are deployed in long-term investments.
PharmGen Science Inc Competitors by Total Liabilities
The table below lists competitors of PharmGen Science Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Krynica Vitamin SA
WAR:KVT
|
Poland | zł104.22 Million |
|
SKILLCAST GROUP LS -001
F:K9I
|
Germany | €9.15 Million |
|
Homeritz Corporation Bhd
KLSE:5160
|
Malaysia | RM25.85 Million |
|
Mistral Gayrimenkul Yatirim Ortakligi AS
IS:MSGYO
|
Turkey | TL1.72 Billion |
|
Eugene SPAC 1
KQ:187790
|
Korea | ₩64.11 Billion |
|
Berlian Laju Tanker Tbk PT
JK:BLTA
|
Indonesia | Rp74.95 Million |
|
Prodways Group SA
PA:PWG
|
France | €44.96 Million |
Liability Composition Analysis (2004–2024)
This chart breaks down PharmGen Science Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 004720 total assets.
Liquidity & Leverage Metrics
PharmGen Science Inc Total Liabilities Ratios Explained
PharmGen Science Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PharmGen Science Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PharmGen Science Inc (2004–2024)
The table below shows the annual total liabilities of PharmGen Science Inc from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩114.02 Billion ≈ $77.27 Million |
+5.86% |
| 2023-12-31 | ₩107.71 Billion ≈ $72.99 Million |
-2.33% |
| 2022-12-31 | ₩110.28 Billion ≈ $74.73 Million |
+18.08% |
| 2021-12-31 | ₩93.39 Billion ≈ $63.29 Million |
+79.69% |
| 2020-12-31 | ₩51.97 Billion ≈ $35.22 Million |
+18.69% |
| 2019-12-31 | ₩43.79 Billion ≈ $29.68 Million |
+5.91% |
| 2018-12-31 | ₩41.35 Billion ≈ $28.02 Million |
+137.26% |
| 2017-12-31 | ₩17.43 Billion ≈ $11.81 Million |
-37.52% |
| 2016-12-31 | ₩27.89 Billion ≈ $18.90 Million |
+56.78% |
| 2015-12-31 | ₩17.79 Billion ≈ $12.06 Million |
-18.86% |
| 2014-12-31 | ₩21.93 Billion ≈ $14.86 Million |
+41.51% |
| 2013-12-31 | ₩15.49 Billion ≈ $10.50 Million |
-7.27% |
| 2012-12-31 | ₩16.71 Billion ≈ $11.32 Million |
-30.76% |
| 2011-12-31 | ₩24.13 Billion ≈ $16.35 Million |
-27.74% |
| 2005-12-31 | ₩33.40 Billion ≈ $22.63 Million |
+35.90% |
| 2004-12-31 | ₩24.58 Billion ≈ $16.65 Million |
+1.67% |
| 2004-09-30 | ₩24.17 Billion ≈ $16.38 Million |
-- |
About PharmGen Science Inc
PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed i… Read more